Meet with our product experts in one-on-one virtual sessions
Set Up a MeetingThe ready availability of high-quality, affordable active pharmaceutical ingredients (APIs) is critical to the delivery of good health to all.
The Dr. Reddy’s API business supplies high quality affordable APIs to leading generic formulations manufacturers across the world, enabling them to accelerate access to affordable medicines for patients worldwide. We are the preferred API partner to pharma companies across the US, Europe, Latin America, Japan, China, Korea and emerging markets.
Our business thrives on the deep technical strengths established over the last 40+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAIs /oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards.
1984
Founded by Dr. Anji Reddy - The company’s first molecule was methyl-dopa, a hyper-tension drug that was unavail-able in India until 1984. The API has been supplied to leading pharma companies worldwide.
1991
From APIs to Formulations – Launch of Omez (Omeprazole). Dr. Reddy’s adds formulation capabilities
1995
Expansion into US, Europe, Russia and EM
2001
First Asia Pacific pharmaceutical company outside Japan to list on the New York Stock Exchange

2010
Dr. Reddy’s announced the launch of Amlodipine Benazepril in the US market.
Dr. Reddy’s launches the first biosimilar darbepoetin alfa in the world and brings relief to millions of anaemia patients and in India under the brand name 'Cresp®', the only one in India.
In the Active Ingredients business, the company filed 36 Drug Master Files (DMFs) in 2009-10. As on 31 March 2010, Dr. Reddy’s had cumulative filings of 378 DMFs, with 156 in the US.
2011
Dr. Reddy’s announced the launch of Pantoprazole Sodium delayed-released tablets.
Dr. Reddy’s launched Levocetirizine tablets, a bioequivalent generic version of Xyzal® in US market.
On October 23, Dr. Reddy’s received an approval and was awarded a 180-day of marketing exclusivity from US FDA for olanzapine 20 mg tablet.
2012
Dr. Reddy’s announced the launch of Atorvastatin Calcium Tablets, a bioequivalent generic version of LIPITOR® in the US market.
Dr. Reddy’s announced the launch of Metoprolol Succinate ER (Extended-Release) Tablet, a bioequivalent generic version of TopropXL® tablets in the US market.

2013
Dr. Reddy’s announced the launch of Zenatane™ (Isotretinoin Capsules USP), a therapeutic equivalent generic version of Accutane® in the US market.
Dr. Reddy’s announced the launch of Divalproex Sodium Extended-Release Tablets, USP, a therapeutic equivalent generic version of Depakote® ER tablet in the US market.
104 new generics products were launched.
577 DMFs were filed in FY2012-13.
2018
Dr. Reddy's Laboratories announces the launch of Hervycta® (trastuzumab biosimilar) in India.
Dr. Reddy's Laboratories receives approval for Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market.

2019
Dr. Reddy's Laboratories announces first-to-market launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial in the U.S. Market.
We are the First Indian Pharma Company to win the national tender for supply of one of the generic drugs (Olanzapine), in China.
2020
Dr. Reddy's Laboratories announces first-to-market launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) Single-dose Prefilled Syringe in the U.S. Market.
Dr. Reddy’s Laboratories announces the launch of FXR™ (obeticholic acid) in India.
Dr. Reddy's Laboratories announces the launch of AVIGAN® (Favipiravir) in India.
Dr. Reddy's Laboratories announces the launch of Redyx in India.

Our company played its part along with the rest of the pharma industry in the fight against COVID-19.
We combined our in-house efforts with an open-innovation model of partnerships to make available a portfolio that included a vaccine, and therapeutics for mild, moderate, and severe COVID-19.
Our focus on agility, access, and affordability helped us reach over 5 million patients during the pandemic, especially in low- and middle-income countries.

Our biggest manufacturing facility in Hyderabad was recognized by the World Economic Forum as part of its Global Lighthouse Network for leadership in the use of Industry 4.0 technologies.
Dr. Reddy's Foundation received a National Award from the President of India for the Empowerment of Persons with Disabilities.
We refreshed our ESG goals to make them bold, measurable, accountable, and central to business strategy.
We were named by the prestigious Science Magazine as among the Top 20 employers globally in pharma/biotech.
We launched Lenalidomide Capsules in the U.S. with two of six strengths eligible for first-to-file, 180-day exclusivity.

We became the first Indian pharma company to debut on the Dow Jones Sustainability World Index.
We launched Nerivio® in India for migraine management, marking our foray into digital therapeutics.
We entered into strategic collaborations for novel molecules - with the U.S.-based Coya Therapeutics for a novel combination biologic for ALS; with China-based Junshi Biosciences for Toripalimab; and with Jiangsu Hengrui for Pyrotinib.
We were included in the Bloomberg Gender-Equality Index for the 6th year in a row.

We diversified our offerings to patients – women’s healthcare in the U.S., consumer healthcare and our first-ever biosimilar in the UK, and vaccines in India.
We agreed with Nestlé India to form a joint venture to introduce health science nutraceutical products to consumers across India and other agreed territories.
We signed a definitive agreement with Haleon plc to acquire Nicotinell and its related portfolio in Nicotine Replacement Therapy, in a significant step towards building a global consumer healthcare business, outside of the US. This is our biggest acquisition yet.

Our Capabilities

R&D
Dr. Reddy’s comprises a strong technical and cross-functional teams including R&D, Quality, Engineering & Analytical departments. Our dedicated R&D teams are committed to developing complex products to meet the evolving API needs in the GMP environment.
Know More
Regulatory
Dr. Reddy’s have an unmatched global regulatory expertise focused on international markets. Our top-class quality and industry-leading compliance are designed to ensure our products meet stringent regulatory requirements globally. Our APIs have regulatory filings available in major markets across the world.
Know More
API Manufacturing
Dr. Reddy's manufactures a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, 180+ active pharmaceutical ingredients (APIs). Our API manufacturing facilities are operated following cGMP (ICH Q7) and regularly inspected by international regulatory authorities. We have eight commercial USFDA inspected production units, six in India and one in Mexico and the UK.
Know MoreSustainability & Social Responsibility

We believe that our strength in innovation, ethical values and focus on bringing critical, life-saving products early to market secures a unique kind of sustainability for us. Our leadership across global markets is indicative of our strong alignment with our ‘Good Health Can’t Wait’ agenda. While we renewed our goals in 2020 to adapt to changing stakeholder expectations, address climate change, and our resolve to work on material issues, we continued to examine more ways to make an impact. We consulted a larger set of global sustainability and pharmaceutical standards and frameworks, and these findings guided our ESG reviews with the leadership and Board.
Combining a top-down and bottom-up approach, using more tools such as our updated enterprise risk management findings, we set 14 bold and ambitious goals across the ESG dimensions to form our vision for 2030. Each of these goals takes into consideration our critical material topics, the external environment in which we operate, and the business and social impact that we can create. In our core API business, our focus on innovation-led affordability gives our customers access to the most complex active ingredients, while maintaining a consistent global quality standard. Our partnerships with leading generic formulation brands to fulfil their drug development needs has also given an edge to our own generics business, enabling us to deliver higher quality at competitive costs.

White Paper: Redyx: Remdesivir formulation developed at Dr. Reddy’s under the license from Gilead


Sacubitril/Valsartan (LCZ696) – Bringing yet another advantage through innovative API offerings


Dr. Reddy’s Flow Chemistry experts share their perspectives in panel discussion of Chemistry Today


A closer look on how Dr. Reddy's met the stringent regulatory requirement of genotoxic impurities in Ranolazine

An API process is a related series of operations which result in the preparation of an active pharmaceutical ingredient. Major operations or steps in an API process may include multi-step chemical synthesis and fermentation, purification, crystallization, drying, milling, packing, labelling, and testing. The final API the progresses towards appropriate characterization and analytical techniques.
The quality of APIs has a significant effect on the efficacy and the safety of medications. Poorly manufactured or adulterated APIs are associated with health issues, illness, or death. So, to ensure the quality and prevent the defects of APIs, regulatory bodies impose stringent rules & screen the APIs thoroughly to ensure medication quality as per the regulatory standards. Violating any of these regulatory standards or procedures can result in huge fines.
免責事項
製品またはサービスへの参照を含むこのカタログの情報は、販売の申し出を構成するものではなく、販売の申し出を表すものとして解釈されるものではありません。有効な特許で保護された製品は、商用目的で提供または提供されません。ただし、そのような規制上の免除が存在する場合は、規制当局への提出を目的として、そのような製品の調査数量が提供される場合があります。購入者は、それぞれの市場の特許シナリオを独自に評価する必要があり、すべての特許関連の責任を負うものとします。インドで有効な特許に基づいて保護されている製品は、商用利用はできませんが、セクション 107A の目的には利用できます。
製品またはサービスへの参照を含むこのカタログの情報は、販売の申し出を構成するものではなく、販売の申し出を表すものとして解釈されるものではありません。有効な特許で保護された製品は、商用目的で提供または提供されません。ただし、そのような規制上の免除が存在する場合は、規制当局への提出を目的として、そのような製品の調査数量が提供される場合があります。購入者は、それぞれの市場の特許シナリオを独自に評価する必要があり、すべての特許関連の責任を負うものとします。インドで有効な特許に基づいて保護されている製品は、商用利用はできませんが、セクション 107A の目的には利用できます。